Ipca Laboratories Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 02, 2026

Key Highlights

The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1531 as of 30 Apr 15:30 . The P/E Ratio of Ipca Laboratories Ltd changed from 30.5 on March 2022 to 21.2 on March 2021 . This represents a CAGR of -7.02% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Ipca Laboratories Ltd changed from ₹ 26921 crore on March 2022 to ₹ 24137 crore on March 2021 . This represents a CAGR of -2.16% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Ipca Laboratories Ltd for the Dec '25 is ₹ 2430 crore as compare to the Sep '25 revenue of ₹ 2584 crore. This represent the decline of -5.96% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Ipca Laboratories Ltd for the Dec '25 is ₹ 571.19 crore as compare to the Sep '25 ebitda of ₹ 514.52 crore. This represent the growth of 11.01% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 364.05 crore over 7 quarters. This represents a CAGR of 41.23% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Ipca Laboratories Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Syncom Formulations (India) Ltd?

Market cap of Ipca Laboratories Ltd is 38,847 Cr while Market cap of Syncom Formulations (India) Ltd is 1,290 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Syncom Formulations (India) Ltd?

The stock performance of Ipca Laboratories Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Syncom Formulations (India) Ltd?

As of May 2, 2026, the Ipca Laboratories Ltd stock price is INR ₹1531.2. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.73.

How do dividend payouts of Ipca Laboratories Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.